Literature DB >> 12504589

Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death.

Hong Guo1, Liching Lai, Matthew E R Butchbach, Chien-liang Glenn Lin.   

Abstract

Abnormal splicing of astroglial glutamate transporter EAAT2 mRNA has been suggested to account for the loss of EAAT2 protein in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). We have identified several clones of human U251 glioma cells which express varying amounts of aberrantly spliced EAAT2 mRNA; these clones do not express any detectable EAAT2 protein. When the wild-type EAAT2 cDNA was expressed in each of these clones, we found that the amount of EAAT2 protein inversely correlated with the levels of endogenous aberrant EAAT2 mRNA. We also observed that ectopic expression of normal EAAT2 protein is toxic to U251 cells as well as to undifferentiated primary astrocytes. We conclude that expression of aberrant EAAT2 mRNA may be one possible mechanism to repress normal EAAT2 protein expression. The implication of this study for the mechanisms of EAAT2 protein loss in ALS and AD is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12504589     DOI: 10.1006/mcne.2002.1198

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  15 in total

Review 1.  Reversal or reduction of glutamate and GABA transport in CNS pathology and therapy.

Authors:  Nicola J Allen; Ragnhildur Káradóttir; David Attwell
Journal:  Pflugers Arch       Date:  2004-08-24       Impact factor: 3.657

Review 2.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Glutamate and the biology of gliomas.

Authors:  John de Groot; Harald Sontheimer
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

4.  Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity.

Authors:  Craig K Colton; Qiongman Kong; Liching Lai; Michael X Zhu; Kathleen I Seyb; Gregory D Cuny; Jun Xian; Marcie A Glicksman; Chien-Liang Glenn Lin
Journal:  J Biomol Screen       Date:  2010-05-27

5.  Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease.

Authors:  Guilian Tian; Qiongman Kong; Liching Lai; Abhik Ray-Chaudhury; Chien-liang G Lin
Journal:  J Neurochem       Date:  2010-02-27       Impact factor: 5.372

Review 6.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

7.  Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia.

Authors:  M L Weller; I M Stone; A Goss; T Rau; C Rova; D J Poulsen
Journal:  Neuroscience       Date:  2008-06-17       Impact factor: 3.590

8.  Complementary neuronal and glial expression of two high-affinity glutamate transporter GLT1/EAAT2 forms in rat cerebral cortex.

Authors:  Peter Kugler; Angelika Schmitt
Journal:  Histochem Cell Biol       Date:  2003-05-20       Impact factor: 4.304

Review 9.  The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects.

Authors:  Yoshikatsu Kanai; Matthias A Hediger
Journal:  Pflugers Arch       Date:  2003-10-07       Impact factor: 3.657

Review 10.  Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.

Authors:  Emily Foran; Davide Trotti
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.